CTKB
NASDAQ
US
Cytek Biosciences, Inc. - Common Stock
$4.53
▲ +$0.05
(+1.12%)
Vol 436K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$645.7M
ROE
-3.4%
Margin
-6.5%
D/E
2.18
Beta
1.31
52W
$2–$7
Wall Street Consensus
11 analysts · Apr 20263
Strong Buy
4
Buy
4
Hold
0
Sell
0
Strong Sell
63.6%
Buy Rating
Price Chart
Similar Stocks
AZTA
Azenta Inc
$1.5B
BLFS
BioLife Solutions Inc
$1.2B
FTRE
Fortrea Holdings Inc
$1.6B
PSNL
Personalis Inc
$706.9M
MLAB
Mesa Laboratories Inc
$433.5M
CYRX
Cryoport Inc
P/E 7.1
$480.7M
MRVI
Maravai LifeSciences Holdings Inc
$831.0M
NAUT
Nautilus Biotechnology Inc
$246.3M
PACB
Pacific Biosciences of California Inc
$564.6M
LAB
Standard BioTools Inc
$492.2M
Earnings
Beat rate: 50.0%
Next Report
May 06, 2026
EPS Estimate: $-0.08
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.08 | — | — |
| Dec 2025 | $-0.02 | $-0.04 | $-0.02 |
| Sep 2025 | $-0.05 | $-0.04 | +$0.01 |
| Jun 2025 | $-0.07 | $-0.04 | +$0.03 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $57.5M | $41.5M | $45.6M | $52.3M | $62.1M |
| Net Income | — | $9.6M | -$11.4M | -$5.6M | -$5.5M | -$44.1M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -1.9% | -1.9% | -1.9% | -1.9% | -3.4% | -3.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -12.2% | -3.3% | -3.3% | -3.3% | -6.5% | -6.5% |
| Gross Margin | 52.3% | 54.4% | 54.4% | 54.4% | 53.5% | 53.5% |
| D/E Ratio | 1.65 | 1.65 | 1.65 | 1.65 | 2.18 | 2.18 |
| Current Ratio | 5.22 | 5.22 | 5.22 | 5.22 | 5.17 | 5.17 |
Key Ratios
ROA (TTM)
-2.6%
P/S (TTM)
3.28
P/B
2.1
EPS (TTM)
$-0.10
CF/Share
$-0.06
Rev Growth 3Y
+16.1%
52W High
$7.30
52W Low
$2.37
$2.37
52-Week Range
$7.30
Financial Health
Free Cash Flow
-$1.8M
Net Debt
-$67.1M
Cash
$90.9M
Total Debt
$23.7M
As of Dec 31, 2025
How does CTKB compare to Life Sciences Tools & Services peers?
Peer group: Small-cap Life Sciences Tools & Services ($300M+) · 25 companies
CTKB valuation vs Life Sciences Tools & Services peers
P/E ratio
—
▼
0%
below
peers
(32.5)
vs Peers
vs Industry
Fair value
P/S ratio
3.3
▼
14%
below
peers
(3.8)
vs Peers
vs Industry
Fair value
P/B ratio
2.1
▼
43%
below
peers
(3.7)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.5%)
vs Peers
vs Industry
Low yield
CTKB profitability vs Life Sciences Tools & Services peers
ROE
-3.4%
▼
2%
below
peers
(-3.3%)
vs Peers
vs Industry
In line
Net margin
-6.5%
▲
31%
above
peers
(-9.4%)
vs Peers
vs Industry
Below avg
Gross margin
53.5%
▲
11%
above
peers
(48.0%)
vs Peers
vs Industry
In line
ROA
-2.6%
▲
0%
above
peers
(-2.6%)
vs Peers
vs Industry
In line
CTKB financial health vs Life Sciences Tools & Services peers
D/E ratio
2.2
▼
94%
below
peers
(36.5)
vs Peers
vs Industry
Above avg
Current ratio
5.2
▲
53%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.3
▼
8%
below
peers
(1.4)
vs Peers
vs Industry
Less volatile
CTKB fundamentals radar
CTKB
Peer median
Industry
CTKB profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CTKB vs peers: key metrics
Latest News
No related news yet